Evidence map›Paper›PMID 33690604›Full record

ArticlePloS one2021

Linking bacterial enterotoxins and alpha defensin 5 expansion in the Crohn's colitis: A new insight into the etiopathogenetic and differentiation triggers driving colonic inflammatory bowel disease.

Tanu Rana, Olga Y Korolkova, Girish Rachakonda, Amanda D Williams, Alexander T Hawkins, Samuel D James, Amos M Sakwe, Nian Hui, Li Wang, Chang Yu and 10 more

Erratum issued Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05663671 (Evaluate Established Anti-DEFA5 mAbs Diagnostic Efficacy and Safety in IBD), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05663671 unknown statusnot on this mapstarted 2023, after this paper: background citation

Evaluate Established Anti-DEFA5 mAbs Diagnostic Efficacy and Safety in IBD

TypeobservationalSponsorMeharry Medical CollegeRan2023 to 2025Enrolled230ConditionsInflammatory Bowel Diseases, Ulcerative Colitis, Crohn Colitis, Indeterminate ColitisArmsDiagnostic Test
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Functional characterization of novel anti-DEFA5 monoclonal antibody clones 1A8 and 4F5 in inflammatory bowel disease colitis tissues.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Mechanisms and regulation of defensins in host defense.Signal transduction and targeted therapy · 2023
    Review
  7. Article
  8. Review
  9. Crohn's disease: Why the ileum?World journal of gastroenterology · 2023
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Tanu RanaDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College School of Medicine, Nashville, Tennessee, United States of America.
Olga Y KorolkovaDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College School of Medicine, Nashville, Tennessee, United States of America.
Girish RachakondaDepartment of Microbiology and Immunology, Meharry Medical College School of Medicine, Nashville, Tennessee, United States of America.
Amanda D WilliamsDepartment of Biology, Lipscomb University, Nashville, Tennessee, United States of America.
Alexander T HawkinsDivision of General Surgery, Section of Colon and Rectal Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Samuel D JamesDepartment of Pathology, Anatomy and Cell Biology, Meharry Medical College School of Medicine, Nashville General Hospital, Nashville, Tennessee, United States of America.
Amos M SakweDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College School of Graduate Studies and Research, Nashville, Tennessee, United States of America.
Nian HuiDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Li WangDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Chang YuDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Jeffrey S GoodwinDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College School of Medicine, Nashville, Tennessee, United States of America.
Michael G IzbanDepartment of Pathology, Anatomy and Cell Biology, Meharry Medical College School of Medicine, Nashville General Hospital, Nashville, Tennessee, United States of America.
Regina S OffodileDepartment of Professional and Medical Education, Meharry Medical College School of Medicine, Nashville General Hospital, Nashville, Tennessee, United States of America.
Mary K WashingtonDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Billy R BallardDepartment of Pathology, Anatomy and Cell Biology, Meharry Medical College School of Medicine, Nashville General Hospital, Nashville, Tennessee, United States of America.
Duane T SmootDepartment of Medicine, Meharry Medical College School of Medicine, Nashville General Hospital, Nashville, Tennessee, United States of America.
Xuan-Zheng ShiDepartment of Medicine, University of Texas Medical Branch (UTMB) in Galveston, Galveston, Texas, United States of America.
Digna S ForbesDepartment of Pathology, Anatomy and Cell Biology, Meharry Medical College School of Medicine, Nashville General Hospital, Nashville, Tennessee, United States of America.
Anil ShankerDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College School of Medicine, Nashville, Tennessee, United States of America.
Amosy E M'KomaDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College School of Medicine, Nashville, Tennessee, United States of America.ORCID 0000-0002-1728-8456
Meharry Medical College · USVanderbilt University · USLipscomb University · USThe University of Texas Medical Branch at Galveston · US

Funding

Endowment for Health Disparities ResearchS21MD000104 · NIMHD · MEHARRY MEDICAL COLLEGE · PI HILDRETH, JAMES E · 2001 to 2016
$73.1M
The RCMI Program in Health Disparities Research at Meharry Medical College - SupplementU54MD007586 · NIMHD · MEHARRY MEDICAL COLLEGE · PI Maureen Sanderson · 2017 to 2026
$48.2M
VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Understanding and Controlling p120 Dysfunction in CRCP50CA095103 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI COFFEY, ROBERT J. · 2002 to 2017
$33.6M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Technologies and Resources CoreU54MD007593 · NIMHD · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS · 2012 to 2018
$24.7M
ROLES OF STATS AND SRC KINASES IN GROWTH CONTROL BY IL17U54CA091408 · NCI · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS · 2001 to 2010
$20.2M
Translational Pathology CoreU54CA163069 · NCI · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS · 2011 to 2025
$18.8M
Training (pp 214-245)P41GM103391 · NIGMS · VANDERBILT UNIVERSITY · PI CAPRIOLI, RICHARD M · 2012 to 2020
$17.7M
TECHNOLOGIES AND RESOURCES FOR CORE LABORATORIESU54RR026140 · NCRR · MEHARRY MEDICAL COLLEGE · PI MURRAY, JOHN J. · 2009 to 2011
$12.9M
Meharry RCMI Program in Women's Health ResearchG12MD007586 · NIMHD · MEHARRY MEDICAL COLLEGE · PI HILDRETH, JAMES E · 2012 to 2016
$7.8M
NCATS NIH HHS UL1 TR000445NCI NIH HHS P50 CA095103NCI NIH HHS R01 CA175370NCI NIH HHS SC1 CA182843NCI NIH HHS U54 CA091405NCI NIH HHS U54 CA091408NCI NIH HHS U54 CA163069NCRR NIH HHS U54 RR026140NCRR NIH HHS UL1 RR024975NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R21 DK095186NIGMS NIH HHS K12 GM068543NIMHD NIH HHS G12 MD007586NIMHD NIH HHS S21 MD000104NIMHD NIH HHS U54 MD007586NIMHD NIH HHS U54 MD007593
6 · The paper itself

Abstract

Evidence link bacterial enterotoxins to apparent crypt-cell like cells (CCLCs), and Alpha Defensin 5 (DEFA5) expansion in the colonic mucosa of Crohn's colitis disease (CC) patients. These areas of ectopic ileal metaplasia, positive for Paneth cell (PC) markers are consistent with diagnosis of CC. Retrospectively, we: 1. Identified 21 patients with indeterminate colitis (IC) between 2000-2007 and were reevaluation their final clinical diagnosis in 2014 after a followed-up for mean 8.7±3.7 (range, 4-14) years. Their initial biopsies were analyzed by DEFA5 bioassay. 2. Differentiated ulcer-associated cell lineage (UACL) analysis by immunohistochemistry (IHC) of the CC patients, stained for Mucin 6 (MUC6) and DEFA5. 3. Treated human immortalized colonic epithelial cells (NCM460) and colonoids with pure DEFA5 on the secretion of signatures after 24hr. The control colonoids were not treated. 4. Treated colonoids with/without enterotoxins for 14 days and the spent medium were collected and determined by quantitative expression of DEFA5, CCLCs and other biologic signatures. The experiments were repeated twice. Three statistical methods were used: (i) Univariate analysis; (ii) LASSO; and (iii) Elastic net. DEFA5 bioassay discriminated CC and ulcerative colitis (UC) in a cohort of IC patients with accuracy. A fit logistic model with group CC and UC as the outcome and the DEFA5 as independent variable differentiator with a positive predictive value of 96 percent. IHC staining of CC for MUC6 and DEFA5 stained in different locations indicating that DEFA5 is not co-expressed in UACL and is therefore NOT the genesis of CC, rather a secretagogue for specific signature(s) that underlie the distinct crypt pathobiology of CC. Notably, we observed expansion of signatures after DEFA5 treatment on NCM460 and colonoids cells expressed at different times, intervals, and intensity. These factors are key stem cell niche regulators leading to DEFA5 secreting CCLCs differentiation 'the colonic ectopy ileal metaplasia formation' conspicuously of pathogenic importance in CC.

Indexed as

Agedalpha-DefensinsCell LineageCells, CulturedColitis, UlcerativeColonCrohn DiseaseEnterotoxinsEpithelial CellsFemaleHumansLogistic ModelsMaleMucin-6Organ Culture TechniquesOrganoidsalpha-DefensinsDEFA5 protein, humanEnterotoxinsMUC6 protein, humanMucin-6

Identifiers

PMID33690604
PMCPMC7942995
OpenAlexW3133652487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.